For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

AOD-9604

Also known as: Anti-Obesity Drug 9604

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (residues 177-191) with an additional N-terminal tyrosine. Developed by Metabolic Pharmaceuticals (Australia) to isolate a purported 'lipolytic' activity of GH without GH-receptor-mediated growth or diabetogenic effects. AOD-9604 is NOT FDA-approved for any indication; controlled human trials for obesity did not demonstrate clinically meaningful weight loss, and obesity development was terminated in 2007.

Where to buy · live market data

Who's worth your money for AOD-9604

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 22 scored sellers

$5.20/mg

$520 · 100mg · 99.9% purity

Best value

Lowest $/mg among scored sellers

$4.00/mg

$400 · 100mg · 99.8% purity

Most tested

11 independent COAs on file

$9.80/mg

$49.00 · 5mg · 99.3% purity

Average price

$10.98/mg

Sellers

77

45-day trend

+17.8%

64 of 77 sellers have a current price· 19 stale hidden· 23 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch AOD-9604

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About AOD-9604

CAS

221231-10-3

Molecular formula

C78H123N23O23S2

Sequence

YLRIVQCRSVEGSCGF

Typical dose range

250–500 mcg/day subcutaneous (research use)

Half-life

~2–3 hours (human); ~3–4 minutes (rat IV, per pharmacokinetic studies)

Independent evidence

COAs for AOD-9604

125 third-party tests across 30 vendors. Each card links to the full report.

All 125 COAs for AOD-9604 →
Measured purity 98.0%–100.0% across 89 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.68 %
Jul 2026
ILS Labs Strong

For

AOD-9604

by NG Peptide· batch AD05-06

Aggregated · 3rd-party listing
99.90 %
Jul 2026
ILS Labs Strong

For

AOD-9604

by Ion Peptide· batch AD10-06172026

✓ Vendor-published
99.90 %
Jul 2026
ILS Laboratories

For

AOD-9604

by Ion Peptide· batch AD10-06172026

COA on file
Aggregated · 3rd-party listing
99.22 %
Jun 2026
Janoshik Analytical Limited

For

AOD-9604

by EZ Peptides· batch EZP-AOD205242026-04

✓ Vendor-published
99.22 %
Jun 2026
Janoshik Analytical Limited

For

AOD-9604

by EZ Peptides· batch EZP-AOD205242026-04

COA on file
Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

AOD-9604

by OROS Research· batch OR-LPAOD5-326-B3

Aggregated · 3rd-party listing
99.46 %
Jun 2026
ILS Labs Strong

For

AOD-9604

by Crush Research· batch R-AOD-5-2605-1

Aggregated · 3rd-party listing
99.45 %
May 2026
Janoshik Analytical Limited

For

AOD-9604

by Prime Peptides· batch 4132026AD

Aggregated · 3rd-party listing
99.65 %
May 2026
Horizon Analytical

For

AOD-9604

by Blank Peptides· batch BP-3713888-P

✓ Vendor-published
99.88 %
May 2026
Kovera Labs

For

AOD-9604

by Ion Peptide· batch AOD5-05142026

COA on file
✓ Vendor-published
99.02 %
May 2026
MZ Biolabs Moderate

For

AOD-9604

by Sports Technology Labs· batch 2026-05-04

COA on file
Aggregated · 3rd-party listing
99.75 %
May 2026
Janoshik Analytical Limited · HPLC

For

AOD-9604

by Skye Peptides· batch AOD26-06-002

Aggregated · 3rd-party listing
99.65 %
May 2026
Horizon Analytical

For

AOD-9604

by Pepsgpt· batch P-3713888-P

Aggregated · 3rd-party listing
99.53 %
May 2026
ILS Labs Strong

For

AOD-9604

by Ion Peptide· batch AOD5-05042026

Aggregated · 3rd-party listing
99.53 %
May 2026
ILS Labs Strong

For

AOD-9604

by Voltera Sciences· batch AOD5.05.02.2026

Aggregated · 3rd-party listing
99.15 %
May 2026
ILS Labs Strong

For

AOD-9604

by Ion Peptide· batch AOD10-05042026

✓ Vendor-published
99.53 %
May 2026
ILS Laboratories

For

AOD-9604

by Ion Peptide· batch COA-2026-B2XTQX

COA on file
✓ Vendor-published
99.19 %
May 2026
ILS Laboratories

For

AOD-9604

by Ion Peptide· batch COA-2026-CEHNLG

COA on file
✓ Vendor-published
99.61 %
Apr 2026
Freedom Diagnostics Moderate

For

AOD-9604

by Ion Peptide· batch AOD10-04222026

COA on file
Aggregated · 3rd-party listing
99.61 %
Apr 2026
Freedom Diagnostics Moderate

For

AOD-9604

by Ion Peptide· batch AOD10-04222026

✓ Vendor-published
99.94 %
Apr 2026
Kovera Labs

For

AOD-9604

by Peptide Partners· batch AO202605

COA on file
Aggregated · 3rd-party listing
99.79 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

AOD-9604

by Peptide Plugs· batch 112-U

Aggregated · 3rd-party listing
99.90 %
Apr 2026
Freedom Diagnostics Moderate

For

AOD-9604

by Kimera Chems· batch KC-AOD-BLK1

Aggregated · 3rd-party listing
99.75 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

AOD-9604

by Qihang Peptide· batch 4

Research depth

14 citations indexed for AOD-9604

All research on AOD-9604 →

review · 2026

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine.

review · 2026

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.

review · 2026

Annual Banned-Substance Review 18th Edition-Analytical Approaches in Human Sports Drug Testing 2024/2025

Alongside the considerable advances and accomplishments in drug research and development, the breadth of anti-doping research topics has also continued to grow.

Study · 2025

Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis

Background The term post-cycle therapy (PCT) often appears in bodybuilding forums in the context of anabolic-androgenic steroids (AAS) cessation. To reduce the negative impact of AAS on the hormonal system, unapproved PCT is used, which consist of medications that help restore hormonal balance.

review · 2017

Human sports drug testing by mass spectrometry

Since the installation of anti-doping rules and regulations and their international enforcement in the mid-1960s, mass spectrometry has been an integral part of doping control procedures.

Study · 2016

Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry

The analysis of low-molecular-mass peptides in doping controls has become a mandatory aspect in sports drug testing and, thus, the number of samples that has to be tested for these analytes has been steadily increasing.